Business
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our portfolio and advancing pipeline at the European Society for Medical Oncology (ESMO) congress taking place from 17-21 October 2025, including new data for PADCEV™ (enfortumab vedotin) plus pembrolizumab in muscle-invasive bladder cancer (MIBC) which will be presented in an ESMO Presidential Symposium on 18 October. In prostate cancer, we are sharing final best-in-class overall survi
About this update from Astellas Pharma Inc.
[{"type":"text","content":"- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"- Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium -","length":190,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Oct. 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our portfolio and advancing pipeline at the European Society for Medical Oncology (ESMO) congress taking place from 17-21 October 2025, including new data for PADCEV™ (enfortumab vedotin) plus pembrolizumab in muscle-invasive bladder cancer (MIBC) which will be presented in an ESMO Presidential Symposium on 18 October. In prostate cancer, we are sharing final best-in-class overall survival data for XTANDI™ (enzalutamide) in high-risk, biochemically recurrent non-metastatic hormone sensitive disease, plus encouraging data for our next-generation bispecific T cell engager ASP2138 in solid tumors, demonstrating continued leadership in CLDN18.2-targeted precision medicine.","length":839,"tagName":"p"},{"type":"image","alt":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","displaySize":"","headline":null,"caption":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":110,"url":"https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gt2H1Ajgjzgw_owZJZe3uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b","width":400,"height":110}},"href":"https://mma.prnewswire.com/media/458529/Astellas_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development, Astellas"As...